Immutep TACTI-002 eftilagimod alpha pembrolizumab HNSCC Phase II 2023

Final results from TACTI-002 Phase II study of eftilagimod alpha combined with pembrolizumab in 37 second-line metastatic head and neck squamous cell carcinoma patients. The combination demonstrated an overall response rate of 29.7% with early onset and durable responses. Safety profile was favorable with no treatment-related deaths, establishing eftilagimod alpha as a promising immunotherapy agent for HNSCC.